<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03947229</url>
  </required_header>
  <id_info>
    <org_study_id>4-2019-0234</org_study_id>
    <nct_id>NCT03947229</nct_id>
  </id_info>
  <brief_title>A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial</brief_title>
  <official_title>A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesized that clopidogrel mono-therapy will not be inferior to the
      extended DAPT in terms of the occurrence of both ischemic and bleeding events, for lesions or
      patients at high risk for either ischemic or bleeding complications 12 months after
      drug-eluting stent (DES) implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients at high risk for either ischemic or bleeding complications, but who were stable
      without clinical events for 12 months after DES implantation will be included in this study.
      Eligible patients will be randomized to continue DAPT (aspirin plus clopidogrel) for further
      24 months or to change to single antiplatelet therapy with clopidogrel (clopidogrel-alone).
      Randomization will be stratified according to 1) clinical presentation (acute coronary
      syndrome or stable coronary artery disease) and 2) age (≥75 or &lt;75). Baseline clinical and
      angiographic characteristics, laboratory findings will be assessed at the time of
      randomization. All patients will provide informed consent on their own initiative. All of
      study subjects will be have an outpatient visit as scheduled in outpatient clinic. Occurrence
      of study endpoints will be documented at clinical visit or telephone interview every 6 months
      since randomization. Antiplatelet drugs will be open-label and prescribed by attending
      physician.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be assigned to continue DAPT (aspirin plus clopidogrel) or to change to single antiplatelet therapy with clopidogrel (clopidogrel-alone) for further 24 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Antiplatelet drugs will be open-label and prescribed by attending physician.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Net Adverse Clinical Events (NACE)</measure>
    <time_frame>24 months</time_frame>
    <description>The composite of all-cause of death, myocardial infarction (MI), stent thrombosis, stroke, or bleeding (BARC type 2, 3, or 5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Each component of net adverse clinical events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause or cardiovascular mortality</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major or minor bleeding</measure>
    <time_frame>24 months</time_frame>
    <description>Major or minor bleeding would be defined by BARC and TIMI criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac event</measure>
    <time_frame>24 months</time_frame>
    <description>Major Adverse Cardiac events includes all-cause of death, myocardial infarctions, stent thrombosis, or stroke.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>DES</condition>
  <arm_group>
    <arm_group_label>Clopidogrel mono-therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After randomization, patients will receive clopidogrel monotherapy after DES implantation for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual-antiplatelet therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive dual antiplatelet consisting of aspirin and clopidogrel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel mono-therapy</intervention_name>
    <description>Patients will receive clopidogrel (75 mg once daily) monotherapy without co-administration of aspirin for 24 months after randomization.</description>
    <arm_group_label>Clopidogrel mono-therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual-antiplatelet therapy</intervention_name>
    <description>Patients will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 24 months after randomization.</description>
    <arm_group_label>Dual-antiplatelet therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients &gt;19 years old

          2. Patients who underwent DES implantation 12 months (+5 months) previously.

          3. High risk characteristics (clinical or lesion) for ischemic events (must at least one)

        High risk patients; clinical criteria

          1. Acute coronary syndrome

          2. Previous history of cerebrovascular accidents

          3. History of peripheral artery intervention

          4. Heart failure (left ventricular ejection fraction ≤40%)

          5. Diabetes treated with medication

          6. Chronic renal insufficiency including end-stage renal diseases

        High risk lesions; angiographic or procedural criteria

          1. Left main diseases

          2. Bifurcation lesions

          3. Chronic total occlusion

          4. In-stent restenotic lesions

          5. Graft lesions

          6. Diffuse long lesions requiring total stent length ≥28 mm

          7. Calcified lesions requiring atherectomy

          8. Multivessel coronary artery disease with multiple stents

          9. Small vessel disease requiring stent diameter of ≤2.5 mm

        Exclusion Criteria:

          1. Age&gt; 80 years

          2. Pregnant women or women with potential childbearing

          3. Life expectancy &lt; 1 year

          4. Refusal or inability to understand of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu 120-752 Seoul, South Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byeong-Keuk Kim, PhD</last_name>
      <phone>82-2-2228-8460</phone>
      <email>kimbk@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients who underwent percutaneous coronary intervention with DES implantation carrying high risks for the recurrent major adverse events.</keyword>
  <keyword>anti platelet therapy</keyword>
  <keyword>bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

